期刊文献+

硼替佐米皮下注射的护理体会 被引量:1

下载PDF
导出
摘要 目的:探讨治疗多发性骨髓瘤硼替佐米采用静脉注射浓度进行皮下注射(1mg/ml)患者的观察要点及护理;方法:注射用硼替佐米3.5mg/支加生理盐水3.5ml溶解,用法为1.0-1.3 mg/m2,于治疗第1、4、8、11天时皮下注射,两次给药之间至少间歇72小时,12天为一疗程;结果:30例患者在化疗期间均未发生严重局部皮肤反应,原发疾病无进展,周围神经病变相比静脉注射后明显减轻。结论:硼替佐米治疗多发性骨髓瘤疗效确切,采取静脉注射浓度进行皮下注射1mg/ml皮下注射,患者对局部不良反应是可以耐受的,并减少了毒副作用。
作者 俞苏英
出处 《生物技术世界》 2015年第5期82-83,共2页 Biotech World
  • 相关文献

参考文献8

  • 1Dimopoulos MA, Terpos E (2010) Multiple myeloma. AnnOncol Off J Eur Soc Med Oncol ESMO 21(Suppl 7):vii143–vii150.doi: 10.1093/annonc/mdq370.
  • 2R ichardson PG, Briemberg H, Jagannath S, Wen PY, BarlogieB, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, SrkalovicG, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ,Najarian K, Esseltine D, Anderson KC, Amato AA (2006) Frequency,characteristics, and reversibility of peripheral neuropathy duringtreatment of advanced multiple myeloma with bortezomib. JClin Oncol Off J Am Soc Clin Oncol 24(19):3113 – 3120. doi:10.1200/JCO.2005.04.7779.
  • 3Bang SM, Lee JH, Yoon SS, Park S, Min CK, Kim CC, Suh C, SohnSK, Min YH, Lee JJ, Kim K, Seong CM, Yoon HJ, Cho KS, Jo DY, LeeKH, Lee NR, Kim CS, Korean Multiple Myeloma Working P (2006) Amulticenter retrospective analysis of adverse events in Koreanpatients using bortezomib for multiple myeloma. Int J Hematol83(4):309 – 313. doi:10.1532/IJH97.A30512.
  • 4Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X,Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, ArnulfB, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de VeldeH, Deraedt W, Harousseau JL (2011) Subcutaneous versus intravenousadministration of bortezomib in patients with relapsedmultiple myeloma: a randomised, phase 3, noninferiority study.Lancet Oncol 12(5):431 – 440. doi:10.1016/ S1470-2045(11)70081-X.
  • 5Kyle RA, Rajkumar SV (2009) Criteria for diagnosis, staging,risk stratification and response assessment of multiple myeloma.Leukemia 23(1):3 – 9. doi:10.1038/leu.2008.291.
  • 6国际骨髓瘤基金会 护士领导委员会(NLB) SQ 硼替佐米白皮书,2012.
  • 7Kamimura T, Miyamoto T, Yokota N, Takashima S, Chong Y, ItoY, Akashi K (2013) Higher incidence of injection site reactionsafter subcutaneous bortezomib administration on the thighcompared with the abdomen. Eur J Haematol 90(2):157 – 161.doi:10.1111/ejh.12055.
  • 8Corthals SL, Kuiper R, Johnson DC, Sonneveld P, Hajek R, vander Holt B, Magrangeas F, Goldschmidt H, Morgan GJ, Avet-Loiseau H (2011) Genetic factors underlying the risk ofbortezomib induced peripheral neuropathy in multiple myelomapatients. Haematologica 96(11):1728 –1732. doi:10.3324/haematol.2011.041434.

同被引文献8

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部